中医药治疗膜性肾病大鼠蛋白尿研究进展OA
Research Progress of TCM in the Treatment of Proteinuria in Rats with Membranous Nephropathy
中医药治疗膜性肾病(membranous nephropathy,MN)大鼠蛋白尿的治法包括益肾活血法、培本固摄法、益肾祛风法、益气活血祛湿法和凉血泄浊解毒法等,代表方药包括健脾益肾活血方、参地颗粒、扶正祛风方、芪龙通肾方、复方蛇龙胶囊等.中药活性成分也具有改善MN大鼠蛋白尿的作用,包括生物碱类、多酚类、萜类、黄酮类等.中药复方和活性成分能够通过抗炎、抗氧化应激、抗细胞凋亡、减少免疫复合物沉积以及抑制肾小球足细胞间充质转化等机制,从而发挥治疗MN的作用.目前的研究存在以下不足:(1)中药活性成分研究多处于实验阶段,缺乏足够的临床证据;(2)中药复方治疗MN的研究缺乏统一的辨证和疗效判定标准;(3)中医药治疗MN蛋白尿的作用机制尚不明确.今后,可开展高质量、多中心、大样本的临床研究以促进成果转化,并进一步研究中医药防治MN蛋白尿的作用靶点和信号通路.
TCM treatments of membranous nephropathy(MN)rats with proteinuria include tonifying kidney and activating blood circu-lation,banking up and strengthening absorption,tonifying kidney and removing wind,nourishing qi and activating blood circulation to e-liminate dampness,cooling blood to expel turbidity and detoxification,etc.The representative formulas include Spleen-Invigorating and Kidney-Replenishing and Blood-Activating Formula,Shendi Granules,Formula for Reinforcing the Healthy Qi and Eliminating Wind,Astragalus and Os Draconis Formula for Dredging the Kidney,Compound Snake-Dragon Capsules,etc.The active ingredients of Chinese drugs also have the effect of improving proteinuria in MN rats,including alkaloids,polyphenols,terpenes,flavonoids,etc.compound for-mulas of Chinese drugs and active ingredients can play a role in the treatment of MN through anti-inflammatory,anti-oxidative stress,an-ti-apoptosis,reducing the deposition of immune complexes and inhibiting glomerular podocyte mesenchymal transformation.The current research has the following deficiencies:(1)The research of Chinese drugs'active ingredients is mostly in the experimental stage,lacking sufficient clinical evidence;(2)The research of compound formulas of Chinese drugs for the treatment of MN lacks unified syndrome differentiation and efficacy judgment standards;(3)The mechanism of TCM in the treatment of MN proteinuria is still unclear.In the fu-ture,clinical trials should be strengthened to promote the transformation of achievements,and high-quality,multi-center,large-sample clinical research should be carried out to further study its target and signal pathway.
张寒;赵幸如;吴宇清;高坤
南京中医药大学附属医院,江苏 南京 210029
中医学
膜性肾病中药复方活性成分蛋白尿
membranous nephropathy(MN)compound formulas of Chinese drugsactive ingredientproteinuria
《河南中医》 2024 (005)
804-810 / 7
青年岐黄学者培养项目{国中医药人教发[2020]7号};江苏省中医药领军人才项目{苏中医科教[2023]17号}
评论